Latest Glycopeptide antibiotics Stories
---DUR001-303 Study Meets Primary & Secondary Endpoints--- DUBLIN, April 24, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303,
One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID LAUSANNE, Switzerland, April 23,
- Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults - DUBLIN, March 2, 2015 /PRNewswire/-- Actavis plc (NYSE: ACT) today announced that
-- Phase 1 Studies Confirm Superior Safety Profile of MRX-I Over Zyvox® -- HAYWARD, Calif. and SHANGHAI, Feb.
Trial also demonstrates strong trends in secondary clinical endpoints AUSTIN, Texas, Feb.
VIENNA and PHILADELPHIA, January 29, 2015 /PRNewswire/ -- Charles Rowland joins Supervisory Board Dr Steven Gelone
Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received fast track designation for ABSSSI (acute bacterial skin and skin structure infections) LAUSANNE, Switzerland,
On October 8, the FDA announced that one lot of Vancomycin Hydrochloride for Injection, USP, by Hospira Inc., is recalled due to uncontrolled storage during transit.
Topical report “Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014” worked out by Global Markets Direct is now available at MarketPublishers.com.
Company Completes Enrollment in Phase 2 Clinical Trial AUSTIN, Texas, Oct.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.